| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
| Sales | 86,550 | 94,140 | 112,250 | 113,340 | 118,900 |
| Sales Growth | -8.06% | -16.13% | -0.96% | -4.68% | +16.45% |
| Net Income | -56,700 | -12,410 | -3,420 | -9,520 | -290 |
| Net Income Growth | -356.89% | -262.87% | +64.08% | -3,182.77% | +96.29% |
Harvard Bioscience (HBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
HARVARD BIOSCIENCE develops, manufactures and markets tools used in drug discovery research at pharmaceutical and biotechnology companies, universities and government laboratories.
Fiscal Year End Date: 12/31